Ignite Creation Date:
2025-12-24 @ 2:08 PM
Ignite Modification Date:
2025-12-27 @ 10:09 PM
Study NCT ID:
NCT01044095
Status:
COMPLETED
Last Update Posted:
2013-07-23
First Post:
2010-01-06
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of Seasonal Influenza Vaccine Against H5N1 Avian Influenza Virus
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D007251', 'term': 'Influenza, Human'}], 'ancestors': [{'id': 'D012141', 'term': 'Respiratory Tract Infections'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D009976', 'term': 'Orthomyxoviridae Infections'}, {'id': 'D012327', 'term': 'RNA Virus Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'BASIC_SCIENCE', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 26}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2009-11'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2013-07', 'completionDateStruct': {'date': '2012-06', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2013-07-22', 'studyFirstSubmitDate': '2010-01-06', 'studyFirstSubmitQcDate': '2010-01-06', 'lastUpdatePostDateStruct': {'date': '2013-07-23', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2010-01-07', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2010-07', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'antibody titers', 'timeFrame': '12 weeks'}], 'secondaryOutcomes': [{'measure': 'safety of 2 doses of seasonal influenza vaccine in healthy adults', 'timeFrame': '12 weeks'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['seasonal influenza vaccine', 'avian influenza H5N1', 'cross reactivity', 'prime boost'], 'conditions': ['Influenza']}, 'referencesModule': {'references': [{'pmid': '23555741', 'type': 'RESULT', 'citation': 'Bethell D, Saunders D, Jongkaewwattana A, Kramyu J, Thitithayanont A, Wiboon-ut S, Yongvanitchit K, Limsalakpetch A, Kum-Arb U, Uthaimongkol N, Garcia JM, Timmermans AE, Peiris M, Thomas S, Engering A, Jarman RG, Mongkolsirichaikul D, Mason C, Khemnu N, Tyner SD, Fukuda MM, Walsh DS, Pichyangkul S. Evaluation of in vitro cross-reactivity to avian H5N1 and pandemic H1N1 2009 influenza following prime boost regimens of seasonal influenza vaccination in healthy human subjects: a randomised trial. PLoS One. 2013;8(3):e59674. doi: 10.1371/journal.pone.0059674. Epub 2013 Mar 26.'}], 'seeAlsoLinks': [{'url': 'http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0059674', 'label': 'Related Info'}]}, 'descriptionModule': {'briefSummary': 'This will be a randomized, open-label, pilot feasibility study of four 2-dose vaccine regimens in healthy volunteers using two commercially available seasonal influenza vaccines to compare immune responses and in vitro cross-reactivity against H5N1. Vaccine doses will be spaced by approximately 8 weeks to allow for optimal prime boost conditions. Humoral, cellular and secretory immune responses will be measured 2 and 4 weeks after each vaccine dose and compared with baseline values.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '49 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Aged 18-49 years.\n2. Healthy as determined by the PI or designate\n3. Willing to give informed consent.\n4. Willing to attend follow-up appointments and undergo study procedures.\n5. US passport holder residing in Bangkok\n6. If military, have a letter of approval for participation from the chain of command (Unit Commander).\n\nExclusion Criteria:\n\n1. History of hypersensitivity to eggs, egg proteins, gentamicin, gelatin or arginine.\n2. Severe or life-threatening reaction to any previous vaccine.\n3. History of chronic respiratory illness, including asthma and sinusitis.\n4. History of heart disease\n5. History of kidney disease\n6. Metabolic disease such as diabetes\n7. Immunocompromised as determined by the PI, or a household contact of an immunocompromised individual.\n8. History of Guillain-Barre syndrome.\n9. Blood disease including sickle cell disease and/or bleeding tendency (by history or based on medical records).\n10. Any influenza vaccination within the previous 6 months, or any other vaccine within 30 days of either dose of influenza vaccine.\n11. Pregnant woman or nursing mother or unwilling to use reliable contraception during the study period until the final day of follow-up.\n12. Blood donation within the preceding 3 months, or screening hemoglobin value of \\<12.5 g/dl.\n13. Receipt of blood products including immunoglobulins within the preceding 3 months.\n14. Receiving any of the following therapies: aspirin, warfarin, theophylline, phenytoin, aminopyrine, immunosuppressive drugs,\n15. Receipt of any antiviral agents within 48 hours of vaccine administration.\n16. HIV positive on screening blood tests.\n17. Any other condition that in the opinion of the study investigator warrants exclusion from the study.'}, 'identificationModule': {'nctId': 'NCT01044095', 'briefTitle': 'Study of Seasonal Influenza Vaccine Against H5N1 Avian Influenza Virus', 'organization': {'class': 'OTHER_GOV', 'fullName': 'Armed Forces Research Institute of Medical Sciences, Thailand'}, 'officialTitle': 'Evaluation of In Vitro Cross-Reactivity With Avian Influenza H5N1 Virus in Healthy Volunteers Vaccinated With a Prime Boost Regimen of Seasonal Influenza Vaccine', 'orgStudyIdInfo': {'id': 'WRAIR1525'}, 'secondaryIdInfos': [{'id': 'HSRRB No. A-15223', 'type': 'OTHER', 'domain': 'Human Subjects Research Review Board'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'Autologous prime boost regimen 1', 'description': 'FluMist® live intranasal vaccine (LAIV) 0.2mL (0.1mL per nostril): 2 doses separated by 8 weeks (+/- 7 days)', 'interventionNames': ['Biological: FluMist® live, attenuated, intranasal seasonal influenza vaccine']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Autologous prime boost regimen 2', 'description': 'Fluzone® inactivated seasonal influenza virus vaccine intramuscularly: 2 doses separated by 8 weeks (+7 days)', 'interventionNames': ['Biological: Fluzone® inactivated influenza virus vaccine']}, {'type': 'EXPERIMENTAL', 'label': 'Heterologous prime boost regimen 1', 'description': 'FluMist® live, intranasal vaccine single dose, followed by Fluzone® inactivated influenza virus vaccine 8 weeks (+/-7 days) later', 'interventionNames': ['Biological: FluMist® live, attenuated, intranasal seasonal influenza vaccine', 'Biological: Fluzone® inactivated influenza virus vaccine']}, {'type': 'EXPERIMENTAL', 'label': 'Heterologous prime boost regimen 2', 'description': 'Fluzone® inactivated seasonal influenza virus vaccine single dose, followed by FluMist® live, intranasal seasonal influenza vaccine 0.2mL 8 weeks (+/- 7 days) later', 'interventionNames': ['Biological: FluMist® live, attenuated, intranasal seasonal influenza vaccine', 'Biological: Fluzone® inactivated influenza virus vaccine']}], 'interventions': [{'name': 'FluMist® live, attenuated, intranasal seasonal influenza vaccine', 'type': 'BIOLOGICAL', 'description': 'FluMist® live, attenuated, intranasal seasonal influenza vaccine 0.2mL (0.1mL per nostril)', 'armGroupLabels': ['Autologous prime boost regimen 1', 'Heterologous prime boost regimen 1', 'Heterologous prime boost regimen 2']}, {'name': 'Fluzone® inactivated influenza virus vaccine', 'type': 'BIOLOGICAL', 'description': 'Fluzone® inactivated influenza virus vaccine 0.5mL intramuscularly', 'armGroupLabels': ['Autologous prime boost regimen 2', 'Heterologous prime boost regimen 1', 'Heterologous prime boost regimen 2']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Bangkok', 'country': 'Thailand', 'facility': 'United States Embassy Medical Unit', 'geoPoint': {'lat': 13.75398, 'lon': 100.50144}}], 'overallOfficials': [{'name': 'Delia B Bethell, BM BCh', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Armed Forces Research Institute of Medical Sciences, Thailand'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Armed Forces Research Institute of Medical Sciences, Thailand', 'class': 'OTHER_GOV'}, 'responsibleParty': {'type': 'SPONSOR'}}}}